Compile Data Set for Download or QSAR
Report error Found 143 Enz. Inhib. hit(s) with all data for entry = 277
TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261893(2-(6-Chloro-9-ethyl-9H-carbazol-3-yl)-1-(2-methoxy...)
Affinity DataIC50: 4.16nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261894(2-(8-Chloro-9-ethyl-9H-carbazol-3-yl)-1-(2-methoxy...)
Affinity DataIC50: 5.19nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261752(3-Amino-4-[(2-methoxyethyl)amino]benzoic acid | US...)
Affinity DataIC50: 5.59nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261760(2-(9-Ethyl-5-fluoro-9H-carbazol-3-yl)-1-(2-methoxy...)
Affinity DataIC50: 6.36nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261864(2-(9-Ethyl-9H-carbazol-3-yl)-4-fluoro-1-(2-methoxy...)
Affinity DataIC50: 6.42nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261884(2-(9-Ethyl-9H-carbazol-3-yl)-1-(tetrahydrofuran-2-...)
Affinity DataIC50: 7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261761(2-(9-Ethyl-8-fluoro-9H-carbazol-3-yl)-1-(2-methoxy...)
Affinity DataIC50: 10.2nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261759(2-(9-Ethyl-7-fluoro-9H-carbazol-3-yl)-1-(2-methoxy...)
Affinity DataIC50: 10.3nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261865(1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)...)
Affinity DataIC50: 11.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261795(3-[2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)...)
Affinity DataIC50: 12.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261785(2-[9-(Cyclopropylmethyl)-9H-carbazol-3-yl]-1-(2-me...)
Affinity DataIC50: 13.1nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261794(9-Ethyl-3-[1-(2-methoxyethyl)-5-(1H-tetrazol-5-yl)...)
Affinity DataIC50: 13.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261881(2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(trifluoromethox...)
Affinity DataIC50: 14.3nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261754(4-Bromo-3-chloro-N-(cyclopropylmethyl)-2-nitroanil...)
Affinity DataIC50: 14.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261766(N-[(3-Chlorophenyl)sulphonyl]-2-(9-ethyl-9H-carbaz...)
Affinity DataIC50: 14.7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261892(2-(9-Ethyl-6-methyl-9H-carbazol-3-yl)-1-(2-methoxy...)
Affinity DataIC50: 15.3nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261815(N-[(2,2-Dimethylpropyl)sulphonyl]-2-(9-ethyl-9H-ca...)
Affinity DataIC50: 16.1nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261846(2-(9-Allyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H...)
Affinity DataIC50: 16.5nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261808(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 16.9nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261803(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 17.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261762(9-Ethyl-5-fluoro-9H-carbazole-3-carbaldehyde | US9...)
Affinity DataIC50: 18nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261888(1-(2-Cyclopropyl-2-hydroxyethyl)-2-(9-ethyl-9H-car...)
Affinity DataIC50: 18.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261756(3-[5-Bromo-4-chloro-1-(cyclopropylmethyl)-1H-benzi...)
Affinity DataIC50: 19.7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261809(N-[(2,6-Dichlorbenzyl)sulphonyl]-2-(9-ethyl-9H-car...)
Affinity DataIC50: 19.8nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261824(1-[2-(Dimethylamino)ethyl]-2-(9-ethyl-9H-carbazol-...)
Affinity DataIC50: 21.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261867(1-(2-Cyclopropylethyl)-2-(9-ethyl-9H-carbazol-3-yl...)
Affinity DataIC50: 22.1nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261866(1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]i...)
Affinity DataIC50: 22.2nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261767(2-Chloro-5-ethyl-5H-pyrido[3,2-b]indole | US970831...)
Affinity DataIC50: 22.8nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261764(9-(2-Methoxyethyl)-9H-carbazole-3-carbaldehyde | U...)
Affinity DataIC50: 23.8nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261883(2-(9-Ethyl-9H-carbazol-3-yl)-1-(oxetan-2-ylmethyl)...)
Affinity DataIC50: 24.5nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261796(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 25.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261781(3-(5-Bromo-4-fluoro-1H-benzimidazol-2-yl)-9-ethyl-...)
Affinity DataIC50: 27.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261765(9-Ethyl-6-methoxy-9H-carbazole-3-carbaldehyde | US...)
Affinity DataIC50: 28.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261782(2-(9-Allyl-9H-carbazol-3-yl)-1-(cyclopropylmethyl)...)
Affinity DataIC50: 28.7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261779(Ethyl 3-amino-4-[(3-methoxypropyl)amino]benzoate |...)
Affinity DataIC50: 30.1nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261768(Methyl 5-ethyl-5H-pyrido[3,2-b]indole-2-carboxylat...)
Affinity DataIC50: 32.2nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261763(1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]i...)
Affinity DataIC50: 33.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261799(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 33.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261784(6-Chloro-9-ethyl-9H-carbazole-3-carbaldehyde and 8...)
Affinity DataIC50: 33.8nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261862(1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)...)
Affinity DataIC50: 34.6nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261802(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 35.3nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261801(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 35.9nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261868(1-(2-Methoxyethyl)-2-(9-propyl-9H-carbazol-3-yl)-1...)
Affinity DataIC50: 36.2nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261817(2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-N-...)
Affinity DataIC50: 36.3nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261816(N-[(2-Chloro-6-methylbenzyl)sulphonyl]-2-(9-ethyl-...)
Affinity DataIC50: 36.9nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261783(1-(Cyclopropylmethyl)-2-(9-methyl-9H-carbazol-3-yl...)
Affinity DataIC50: 39.4nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261825([2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1...)
Affinity DataIC50: 41.3nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261780(2-(9-Ethyl-9H-carbazol-3-yl)-N,1-bis(2-methoxyethy...)
Affinity DataIC50: 42.8nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261856(5-[2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)...)
Affinity DataIC50: 43.7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261869(1-(2-Methoxyethyl)-2-[9-(prop-2-yn-1-yl)-9H-carbaz...)
Affinity DataIC50: 43.7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

Displayed 1 to 50 (of 143 total ) | Next | Last >>
Jump to: